Copertina

Neoadjuvant Atezolizumab and chemotherapy for non-squamous non-small cell lung cancer: efficacy and safety results of an open-label, single-arm, phase II trial

Immune checkpoint inhibitors have shown promising results in the neoadjuvant treatment of resectable non-small cell lung cancer. This open-label, single-arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in patients with...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Niedermaier, Benedikt Walter (Autore) , Bochtler, Tilmann (Autore) , Eichhorn, Florian (Autore) , Griffo, Raffaella (Autore) , Klotz, Laura Valentina (Autore) , Allgäuer, Michael (Autore) , Stenzinger, Albrecht (Autore) , Bischoff, Helge (Autore) , Schneider, Marc (Autore) , Christopoulos, Petros (Autore) , Haberkorn, Uwe (Autore) , Heußel, Claus Peter (Autore) , Zörnig, Inka (Autore) , Herth, Felix (Autore) , Thomas, Michael (Autore) , Rölle, Alexander (Autore) , Winter, Hauke (Autore) , Benner, Axel (Autore) , Jäger, Dirk (Autore) , Eichhorn, Martin E. (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 2026
In: International journal of cancer
Year: 2026, Pages: 1-11
ISSN:1097-0215
DOI:10.1002/ijc.70508
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.70508
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.70508
Testo
Note sull'autore:Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn
Descrizione
Riassunto:Immune checkpoint inhibitors have shown promising results in the neoadjuvant treatment of resectable non-small cell lung cancer. This open-label, single-arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in patients with resectable non-squamous non-small cell lung cancer. Patients with previously untreated, pathologically confirmed, non-squamous non-small cell lung cancer in stage II, IIIA, and select IIIB (T3N2 only) were treated with atezolizumab and carboplatin/nab-paclitaxel for 3 cycles followed by curative intent surgery. Major pathologic response (MPR) was defined as primary endpoint. 20 patients with histologically confirmed pulmonary adenocarcinoma in TNM-stage IIA (n = 1, 5%), stage IIB (n = 7, 35%), and stage IIIA (n = 12, 60%) were enrolled and treated according to the study protocol. 151 treatment-related adverse events were recorded, and 13 patients (65%) had treatment-related adverse events of grade 3 or higher. There were no grade 5 events. All patients underwent complete anatomical resection (R0). MPR was observed in 9 patients (45%), including 5 (25%) patients with complete pathological response. The proportion of remaining viable tumor showed a significant but weak association to the relative tumor size change in CT (p = 0.018) and the relative change in SUVmax (p = 0.006). In conclusion, neoadjuvant chemoimmunotherapy with atezolizumab achieved a promising MPR-rate of 45% while being well tolerated and allowing a safe and complete surgical resection. These results strongly support the further investigation of atezolizumab as preoperative therapy in resectable non-small cell lung cancer and underline the continued need to develop biomarkers of response.
Descrizione del documento:Gesehen am 11.06.2026
Descrizione fisica:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.70508

Documenti analoghi